Inhibition of monoacylglycerol lipase reduces nicotine reward in the conditioned place preference test in male mice

NEUROPHARMACOLOGY

卷:176

Article

Muldoon, Pretal P.¹  Akinola, Lois S.²  Schlosburg, Joel E.²  Lichtman, Aron H.²  Sim-Selley, Laura J.²  Mahadevan, Anu³  Cravatt, Benjamin F.⁴  Damaj, M. Imad² 

[1] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Med Coll Virginia Campus, Richmond, VA USA

[2] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Med Coll Virginia Campus, Richmond, VA 23298 USA

[3] Organix Inc, 240 Salem St, Woburn, MA USA

[4] Scripps Res Inst, Dept Chem, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA

关键词: Nicotine;    Nicotine reward;    Endocannabinoids;    Monoacylglycerol lipase (MAGL);    2-Arachidonylglycerol (2-AG);    Conditioned place preference;   

DOI  :  10.1016/j.neuropharm.2020.108170

来源: Elsevier

【 摘 要 】

Nicotine, the primary psychoactive component in tobacco, plays a major role in the initiation and maintenance of tobacco dependence and addiction, a leading cause of preventable death worldwide. An essential need thus exists for more effective pharmacotherapies for nicotine-use cessation. Previous reports suggest that pharmacological and genetic blockade of CB1 receptors attenuate nicotine reinforcement and reward; while exogenous agonists enhanced these abuse-related behaviors. In this study, we utilized complementary genetic and pharmacologic approaches to test the hypothesis that increasing the levels of the endocannabinoid 2-arachindonoylglycerol (2-AG), will enhance nicotine reward by stimulating neuronal CB1 receptors. Contrary to our hypothesis, we found that inhibition of monoacylglycerol lipase (MAGL), the primary catabolic enzyme of 2-AG, attenuates nicotine conditioned place preference (CPP) in mice, through a non-CB1 receptor-mediated mechanism. MAGL inhibition did not alter palatable food reward or Lithium Chloride (LiCl) aversion. In support of our findings, repeated MAGL inhibition did not induce a reduction in CB1 brain receptor levels or hinder function. To explore the potential mechanism of action, we investigated if MAGL inhibition affected other fatty acid levels in our CPP paradigm. Indeed, MAGL inhibition caused a concomitant decrease in arachidonic acid (AA) levels in various brain regions of interest, suggesting an AA cascade-dependent mechanism. This idea is supported by dose-dependent attenuation of nicotine preference by the selective COX-2 inhibitors valdecoxib and LM-4131. Collectively, these findings, along with our reported studies on nicotine withdrawal, suggest that inhibition of MAGL represents a promising new target for the development of pharmacotherapies to treat nicotine dependence.

【 授权许可】

Free